What happens to Alexion stock after merger?
The Alexion shares will be delisted from the Nasdaq Stock Market and Alexion will terminate its registration under the U.S. Securities Exchange Act of 1934 as soon as practicable following completion of the acquisition.
Did AstraZeneca buy Alexion?
AstraZeneca has completed the acquisition of Alexion Pharmaceuticals, Inc., marking its entry into medicines for rare diseases.
Is AZ buying Alexion?
AZ on Wednesday announced the completion of its Alexion acquisition, a week after securing a pivotal nod from the U.K.’s Competition and Markets Authority (CMA).
How much is AstraZeneca buying Alexion for?
$39 billion
AstraZeneca is splashing out $39 billion to buy Alexion in a cash-and-stock deal, the British pharma revealed Saturday. The deal is driven by AstraZeneca’s desire to build a stronger presence in immunology—and to give its top line an immediate boost.
Is Alexion a takeover target?
Granted, Alexion Pharmaceuticals isn’t the industry’s most exciting acquisition target, but this deal will most likely work out well for investors in the long run.
How did AstraZeneca acquire Alexion?
The acquisition will be undertaken through a US statutory merger in which Alexion shareholders will receive $60 in cash and 2.1243 new AstraZeneca ADSs listed on the Nasdaq exchange for each of their Alexion shares.
Who owns Alexion Pharmaceuticals?
AstraZenecaAlexion Pharmaceuticals / Parent organization
Who owns Alexion?
Who owns AstraZeneca shares?
The company is a wholly owned subsidiary of AstraZeneca plc, a United Kingdom-based pharmaceutical company.
When did AstraZeneca buy Alexion?
The boards of directors of both companies have unanimously approved the acquisition. Subject to receipt of regulatory clearances and approval by shareholders of both companies, the acquisition is expected to close in Q3 2021, and upon completion, Alexion shareholders will own c. 15% of the combined company.
Is Moderna better than Pfizer vaccine?
Boston, MA – Compared with the Pfizer COVID-19 vaccine, the Moderna COVID-19 vaccine has a slightly lower risk of COVID-19 outcomes, including documented SARS-CoV-2 infection, symptomatic COVID-19, and COVID-19-related hospitalization, intensive care unit (ICU) admission, and death, over a 24-week period, according to …